1-氰甲基-4-苯甲基哌嗪 | 92042-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-氰甲基-4-苯甲基哌嗪
• 中文别名: (4-苄基哌嗪-1-基)乙腈
• 英文名称: 1-benzyl-4-(cyanomethyl)piperazine
• 英文别名: 1-(cyanomethyl)-4-benzylpiperazine；2-(1-benzylpiperazin-4-yl)acetonitrile；2-(4-benzylpiperazin-1-yl)acetonitrile；4-Benzyl-piperazinyl-(1)-acetonitril；(4-benzyl-piperazin-1-yl)-acetonitrile；(4-benzyl-1-piperazinyl)acetonitrile；4-benzylpiperazine-1-acetonitrile；1-Cyanmethyl-4-benzyl-piperazin
• CAS: 92042-93-8
• 化学式: C₁₃H₁₇N₃
• mdl: MFCD00078192
• 分子量: 215.298
• InChiKey: ATUPEPBRQNHPDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-氰甲基-4-苯甲基哌嗪 在 钯 palladium diacetate 、 lithium aluminium tetrahydride 、 甲酸 、 溶剂黄146 、 三乙胺 、 三(邻甲基苯基)磷 、 silver carbonate 、 苯酚 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.5h， 生成 2,3-Dimethoxy-12-(2-piperazin-1-yl-ethyl)-12H-8,10-dioxa-6,12-diaza-cyclopenta[b]chrysen-13-one
  参考文献：
  名称：

  5-(2-Aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones:  Variation of N-Alkyl Substituents Modulates Sensitivity to Efflux Transporters Associated with Multidrug Resistance

  摘要：

  5H-8,9-Dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxydibenzo [c, h]-[1,6]naphthyridin-6-one (ARC-111) has potent TOP1-targeting activity and pronounced antitumor activity. Several analogues of ARC-111 were synthesized with NH2, N-alkyl, N,N-dialkyl, pyrrolidinyl, piperidinyl, and piperazinyl substituents at the 2-position of the 5-ethyl group. The relative TOP1-targeting activity and cytotoxicity of these structural analogues were assessed in RPMI8402 and P388 tumor cells and their camptothecin-resistant variants CPT-K5 and P388/CPT45, respectively. Potent TOP1-targeting activity was retained within a series of mono N-alkyl analogues that included NHCH2CH3, NHCH(CH3)(2), and NHC(CH3)(3). TOP1-targeting activity was diminished by the presence of a N-benzyl moiety. In a comparison of a series of N-alkyl-N-isopropyl analogues, activity decreased in the order CH3 > CH2CH3 > CH(CH3)(2). Cytotoxicity in RPMI8402 and P388 did correlate with TOP1-targeting activity. Cytotoxic activity was also determined in KB3-1 cells and its variants KB/V-1 and KBH5.0. As KB/V-1 cells overexpress MDR1 and KBH5.0 cells overexpress BCRP, decreased cytotoxicity in these cell lines relative to the parent cell line is indicative of compounds that are substrates for these efflux transporters. In view of their diminished cytotoxicity in KB/V-1 cells, it appears that the likely demethylated metabolites of ARC-111, i.e., where NH2 or NHCH3 replaces the N(CH3)(2) at the 2-position of the 5-ethyl substituent, are substrates for MDR1. In contrast, no significant difference in cytotoxicity among these three cell lines was observed with other N-alkyl analogues, including NHC2H5, NHCH(CH3)(2), NHC(CH3)(3), N(CH3)(2), N(CH2CH3)(2), NCH3(CH(CH)(3))(2)), and either the pyrrolidinyl or the piperidinyl analogues. The 2-(piperazinyl) analogues were associated with diminished cytotoxicity in KB/V-1 cells, suggesting that the second basic amino substituent is associated with their recognition as substrates by MDR1. Comparative studies on the antitumor activity of ARC-111 and its N-demethylated derivatives (the NHCH3 and NH2 analogues) against SJ-BT45 medulloblastoma xenografts in scid mice revealed that the secondary amine metabolite is at least as active as ARC-111 in vivo, although the primary amine derivative was significantly less potent.

  DOI：

  10.1021/jm049447z
• 作为产物：
  描述：

  1-苄基哌嗪 以 甲醇 、 水 、 二甲基亚砜 为溶剂， 生成 1-氰甲基-4-苯甲基哌嗪
  参考文献：
  名称：

  N-烷基和N-芳基哌嗪的新型氰基衍生物的合成，表征和体外生物学研究。

  摘要：

  已合成了N-烷基和N-芳基哌嗪的氰基衍生物，并筛选了其抗菌和抗真菌活性。所有合成的化合物均显示出对金黄色葡萄球菌（MTCCB 737），铜绿假单胞菌（MTCCB 741），表皮链霉菌（MTCCB 1824）和大肠杆菌（MTCCB 1652）的致病菌株的抗菌活性以及对曲霉（F. 4517），黄曲霉（ITCC 5192）和黑曲霉（ITCC 5405）。所有化合物均显示轻至中度的抗菌活性。但是，化合物3c，4a和6对研究中使用的致病菌株显示出强大的抗菌活性。化合物3a，3b，4b和4d对曲霉病原菌表现出轻度至中度的抗真菌活性。使用MTT比色测定法对Hela细胞评估了该研究中报道的化合物的细胞毒性。所有化合物均显示出比对照药物庆大霉素更高的细胞生存力，其中化合物2具有最高的细胞生存力，即95％。

  DOI：

  10.1016/j.ejmech.2006.10.009

文献信息

• Design, Synthesis, and Structure−Activity Relationships of a Series of 3-[2-(1-Benzylpiperidin-4-yl)ethylamino]pyridazine Derivatives as Acetylcholinesterase Inhibitors
  作者：Jean-Marie Contreras、Isabelle Parrot、Wolfgang Sippl、Yveline M. Rival、Camille G. Wermuth

  DOI：10.1021/jm001088u

  日期：2001.8.1

  Starting from the 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-6-phenylpyridazine 1, we performed the design, the synthesis, and the structure-activity relationships of a series of pyridazine analogues acting as AChE inhibitors. Structural modifications were achieved on four different parts of compound 1 and led to the following observations: (i) introduction of a lipophilic environment in the C-5 position

  从3- [2-（1-苄基哌啶-4-基）乙基氨基] -6-苯基哒嗪1开始，我们进行了一系列作为AChE抑制剂的哒嗪类似物的设计，合成和结构-活性关系。在化合物1的四个不同部分进行了结构修饰，得出以下结论：（i）在哒嗪环的C-5位引入亲脂性环境有利于AChE抑制活性和AChE / BuChE选择性; （ii）C-6苯基的取代和各种取代是可能的，并导致等同或稍微活性更高的衍生物；（iii）苄基哌啶部分的等排取代或修饰对活性是有害的。在所有准备好的衍生物中，茚并哒嗪衍生物4g被发现是更有效的抑制剂，在电鳗AChE上的IC（50）为10 nM。与化合物1相比，其效力提高了12倍。此外，IC [50]为21 nM的3- [2-（1-苄基哌啶-4-基）乙基氨基] -5-甲基-6-苯基哒嗪4c对人AChE的选择性高100倍（人BuChE / AChE之比为24）比参比他克林。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：PANO THERAPEUTICS INC

  公开号：WO2021055637A1

  公开（公告）日：2021-03-25

  Provided herein are compounds, such as compounds for use in treating cancer. Also provided are methods of treating cancer, including treatment resistant cancer or cancer associated with a hypoxic tumor.

  本文提供了化合物，例如用于治疗癌症的化合物。还提供了治疗癌症的方法，包括治疗耐药癌症或与缺氧肿瘤相关的癌症的方法。
• Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ₁ Receptor Antagonists for the Treatment of Pain
  作者：Mónica García、Virginia Llorente、Lourdes Garriga、Ute Christmann、Sergi Rodríguez-Escrich、Marina Virgili、Begoña Fernández、Magda Bordas、Eva Ayet、Javier Burgueño、Marta Pujol、Albert Dordal、Enrique Portillo-Salido、Georgia Gris、José Miguel Vela、Carmen Almansa

  DOI：10.1021/acs.jmedchem.1c00417

  日期：2021.7.22

  A new series of propionamide derivatives was developed as dual μ-opioid receptor agonists and σ1 receptor antagonists. Modification of a high-throughput screening hit originated a series of piperazinylcycloalkylmethyl propionamides, which were explored to overcome the challenge of achieving balanced dual activity and convenient drug-like properties. The lead compound identified, 18g, showed good analgesic

  开发了一系列新的丙酰胺衍生物作为μ阿片受体双重激动剂和σ1受体拮抗剂。对高通量筛选命中的修饰产生了一系列哌嗪基环烷基甲基丙酰胺，其被探索以克服实现平衡的双重活性和方便的类药特性的挑战。鉴定出的先导化合物18g在多种急性（爪压）和慢性（部分坐骨神经结扎）疼痛动物模型中显示出良好的镇痛效果，与羟考酮相比，胃肠道影响减轻。
• Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of [.beta.-(aroylamino)ethyl]piperazines and -piperidines and [2-[(arylamino)carbonyl]ethyl]piperazines, -piperidines, -pyrazinopyridoindoles, and -pyrazinoisoquinolines. A new class of potent H1 antagonists
  作者：Mridula Saxena、Shiv K. Agarwal、G. K. Patnaik、Anil K. Saxena

  DOI：10.1021/jm00173a011

  日期：1990.11

  Some [beta-(Aroylamino)ethyl]piperazines and -piperidines and [2-[(Arylamino)carbonyl]ethyl]piperazines, -piperidines, -pyrazinopyridoindoles, and -pyrazinoisoquinolines have been synthesized and their H1-antagonistic activity studied in isolated guinea pig ileum. Quantitative structure-activity relationship analysis indicates that the hydrophobicity of the side chain of these compounds plays a major

  已经合成了一些[β-（芳酰基氨基）乙基]哌嗪和-哌啶和[2-[（芳基氨基羰基]乙基]哌嗪，-哌啶，-吡嗪并吡啶并吲哚和-吡嗪并异喹啉，并在分离的豚鼠中研究了它们的H1-拮抗活性。回肠。定量的构效关系分析表明，这些化合物侧链的疏水性在其活性中起主要作用，而空间和电子因素则次要。所有这些化合物都作用于共同的受体，并似乎与该受体发生类似的相互作用。
• Pyridine and pyridazine derivatives, processes for the production
  申请人：Boehringer Mannheim GmbH

  公开号：US05786371A1

  公开（公告）日：1998-07-28

  Compounds of Formula I ##STR1## in which the variables are defined herein, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of diseases which are the result of thromboembolytic events.

  式I的化合物##STR1##，其中变量在此处定义，其生产过程以及包含这些化合物的药物制剂，用于治疗由血栓栓塞事件引起的疾病。